Tumorresponse monitoring in patients with breast cancer treated with primary systemic therapy: Towards predicting response in both the primary tumor and in axillary lymph nodes
- Conditions
- breast cancercarcinoma10006291
- Registration Number
- NL-OMON31961
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
Inclusion in one of the clinical protocols that are part of the NKI-AVL neoadjuvant therapy program; women with breastcancer > 3 cm and/or axillary lymph node metastasis
Exclusion Criteria
Exclusion in one of the clinical protocols that are part of the NKI-AVL neoadjuvant therapy program; Pregnancy or breastfeeding
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Sensitivity and specificity of FDG PET and MRI to assess early tumour response<br /><br>of the primary tumour<br /><br>Sensitivity and specificity of FDG PET/CT and seed localisation in measuring<br /><br>(early) tumour response of the axilla. </p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>